Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Assam Govt Upholds Validity of Pharmacy Council Election, Council Constituted
    30 January 2026

    Assam Govt Upholds Validity of Pharmacy Council Election, Council Constituted

    The Government of Assam has formally upheld the validity of the Assam Pharmacy Council (APC) election held in February 2024 and confirmed the constitution of the Council, bringing an end to all disputes related to the election process.

  • 30 January 2026
    Roche Reports Strong 2025 Performance, Lifts Outlook as Pharma Sales Drive Growth
    Swiss pharmaceutical and diagnostics giant Roche Group reported a strong financial performance for full-year 2025, with group sales rising 7 % at constant exchange rates, driven by solid demand for both medicines and diagnostic solutions, the company said in a media release on Thursday.
  • 29 January 2026
    CGHS notifies Senior Pharmacist RRs, grants Group ‘B’ Status amid dissent
    Central Government Health Scheme, CGHS, Ministry of Health and Family Welfare, marking a major structural shift in the pharmacy cadre. For the first time, CGHS pharmacists are eligible for promotion to a Group B, Non-Gazetted post.
  • 29 January 2026
    Astrazeneca plans USD 15b investment in China through 2030 to boost R&D, manufacturing

    British pharmaceutical firm AstraZeneca PLC announced on Thursday it will commit usd 15 billion (about ₹1.2 lakh crore) to expand research, development and manufacturing operations in China through 2030, underscoring the country’s growing importance in global drug innovation and production.

    The investment, detailed in a company press release, aims to bolster AstraZeneca’s capabilities across the entire drug value chain from discovery and clinical development to large-scale manufacturing, particularly in cell therapies and radioconjugates, two areas of rapid scientific advance.

  • 29 January 2026
    New Alzheimer Europe Report Projects 64% Increase in Dementia Across Europe by 2050

    Alzheimer Europe today released a new report titled “The Prevalence of Dementia in Europe 2025”, projecting a substantial rise in the number of people living with dementia across the continent over the next quarter-century. The report updates prevalence figures using recent community-based studies and United Nations population projections for 2025 and 2050.

  • 28 January 2026
    Lonza Posts Strong FY2025 Results, Forecasts 11–12% Sales Growth in 2026
    Swiss contract development and manufacturing organization Lonza Group AG reported strong full-year results for 2025 and outlined its growth expectations for 2026.
  • 28 January 2026
    Centre proposes Mandatory Blue Line on Labels of Antimicrobial Medicines

    The Union Ministry of Health and Family Welfare has released a draft notification proposing a distinct blue vertical line on the labels of all antimicrobial medicines, a move aimed at improving identification and promoting the rational use of antibiotics in the country.

  • 28 January 2026
    CDSCO eases Test Licence Pathway, cuts approval timelines under NDCT Rules Amendment 2026

    In a move aimed at accelerating drug development while maintaining regulatory oversight, India’s drug regulator has notified sweeping changes to the New Drugs and Clinical Trials (NDCT) Rules, 2019, introducing a faster “prior intimation” route for select test licences and sharply reducing approval timelines.

    The amendments, notified on January 20, 2026, under G.S.R. 46(E), mark a significant shift in how manufacturers can produce new drugs and investigational products for clinical trials, bioavailability, bioequivalence studies, and analytical testing

  • 27 January 2026
    Sun Pharma Gets DCGI Nod for Generic Semaglutide Injection for Weight Management in India
    Sun Pharmaceutical Industries Ltd on Tuesday said it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection for chronic weight management in adults. The approval follows the successful review of a Phase III clinical trial conducted in India, the company said in a statement.
  • 27 January 2026
    China’s Drug Regulator Suspends Import, Sale and Use of Two Indian-Manufactured Medicines over Quality Compliance Failures
    Chinas National Medical Products Administration (NMPA) announced on January 26 that it has suspended the import, sale and use of two pharmaceutical products manufactured in India after regulatory inspections uncovered significant deficiencies in production quality and compliance with Chinese standards.
Subscribe to Pharma News